The article discusses advancements in gout treatment research, focusing on new drug candidates like dotinurad from Crystalys Therapeutics. Key points include:
-
Crystalys Therapeutics' Dotinurad:
- Crystalys acquired the rights to develop and commercialize dotinurad in North America, Europe, Middle East, and North Africa.
- The company is conducting Phase III trials (RUBY and TOPAZ) to evaluate dotinurad's efficacy compared with allopurinol for lowering serum uric acid levels.
-
Sobi’s Pozdeutinurad:
- Sobi recently acquired Arthrosi Therapeutics, gaining rights to pozdeutinurad.
- Pozdeutinurad has shown positive Phase III results and is expected to generate blockbuster sales of $1.075 billion in the U.S. alone.
-
Other Gout Drugs:
- Olatec's dapansutrile (OLT1177) is under study for acute gout flares.
- JW Pharmaceutical’s epaminurad is nearing completion of a Phase III trial comparing it to febuxostat.
- Atom
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
3
Ali NematiWritten by Ali
